An intravenous monoclonal antibody (passive immunotherapy) for the treatment of patients with mild early-stage Alzheimer’s disease.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Cometriq (Cabozantinib)
An oral agent for the treatment of progressive unresectable or metastatic medullary thyroid cancer.
Trevo® Pro / Trevo® ProVue™ Retrieval System
A microcatheter with an integrated stent-like retriever device for revascularization in patients with acute ischemic stroke who are ineligible for or who fail intravenous tissue plasminogen activator therapy.
Zilver® PTX® Paclitaxel-Eluting Peripheral Arterial Stent
A polymer-free, paclitaxel-eluting, self-expanding nitinol stent for treatment of de novo and restenotic lesions up to 140 mm long in patients with symptomatic femoropopliteal peripheral artery disease above the knee.
Absorb™ Bioresorbable Vascular Scaffold (BVS)
A fully bioabsorbable, everolimus-eluting, coronary artery stent designed to eliminate the need for long-term antiplatelet therapy.
somo•v® Automated Breast Ultrasound System
An automated, whole-breast, three-dimensional ultrasound scanning system for breast cancer screening in patients with dense breasts, used as an adjunct to x-ray mammography.
Xeljanz® (Tofacitinib)
An oral Janus kinase inhibitor for the treatment of moderate to severe rheumatoid arthritis.
Xarelto® (Rivaroxaban) for Treatment of Acute Venous Thromboembolism (VTE) and VTE Secondary Prevention
An oral factor Xa direct inhibitor for the treatment of acute venous thromboembolism (VTE) and prevention of VTE recurrence.
Stivarga® (Regorafenib) for Metastatic Colorectal Cancer
Oral multikinase inhibitor for the third-line treatment of chemorefractory metastatic colorectal cancer.
Genous™ Bio-Engineered R Stent
A coronary artery stent coated with anti-CD34 antibodies, designed to obviate the need for prolonged antiplatelet therapy after implantation.